Clinical EfficacyEsperion’s partner Otsuka Pharmaceuticals announced that BDA met the primary endpoint of cholesterol lowering in a Phase 3 trial, demonstrating significant LDL-C reductions compared to placebo.
Japanese Market EntryEsperion's entry into the Japanese market represents a major step forward as Japan is one of the top three global markets for cardiovascular prevention.
Market ExpansionRegulatory approval for NEXLETOL in Japan marks a key milestone in commercial expansion, allowing Esperion to receive milestone payments and royalties based on net sales achievements by partner Otsuka Pharmaceuticals.